IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026

뉴스 본문을 불러오고 있어요.

IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026 | 웨이프 WAPE

IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026

기사 요약

관련 종목

댓글 —